<DOC>
	<DOCNO>NCT00945958</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety SPARC0913 . A multicenter , open label , non-randomized , uncontrolled , single group assignment , safety study subject primary open angle glaucoma ocular hypertension plan . Subjects receive study medication period 24-weeks .</brief_summary>
	<brief_title>Evaluation Safety SPARC0913 Open Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description>This multicenter , open label , non-randomized , single-arm , extension safety study evaluate long-term safety SPARC0913 . Subjects complete prior evaluator-masked clinical non-inferiority Study participate current study .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Men woman age â‰¥18 year Willing participate give write informed consent Willing commit study medicationdosing , study visit followup visit complete evaluation Eligible receive Latanoprost daily monotherapy treatment glaucoma History allergic hypersensitivity poor tolerance latanoprost History Substance abuse addiction ( alcohol drug ) past 3 year History chronic use concomitant medication neurologic psychiatric illness would affect assessment safety effectiveness study medication Any abnormality prevent IOP measurement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
</DOC>